AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Liver TransplantationTransplantation, HomologousHematopoietic Stem Cell TransplantationKidney TransplantationBone Marrow TransplantationHematopoietic Stem CellsTransplantation, AutologousTransplantation ConditioningHeart TransplantationLung TransplantationStem Cell TransplantationGraft SurvivalOrgan TransplantationTissue DonorsGraft vs Host DiseaseTransplantation ChimeraGraft RejectionHematopoiesisPancreas TransplantationTransplantationTransplantation ImmunologyHematopoietic SystemIslets of Langerhans TransplantationCell TransplantationBone Marrow CellsImmunosuppressive AgentsHematologic NeoplasmsCord Blood Stem Cell TransplantationTreatment OutcomeTransplantation, IsogeneicAntigens, CD34Living DonorsWhole-Body IrradiationHistocompatibility TestingTime FactorsTransplantation, HeterotopicLeukemiaHeart-Lung TransplantationPeripheral Blood Stem Cell TransplantationCell DifferentiationTransplantation ToleranceRetrospective StudiesTissue and Organ ProcurementHistocompatibilityImmunosuppressionBone MarrowFetal Tissue TransplantationMice, Inbred C57BLMyeloablative AgonistsInterleukin-3RecurrenceTransplantation, HeterologousLiver FailureSkin TransplantationColony-Forming Units AssayPostoperative ComplicationsCells, CulturedSurvival AnalysisCell LineageCyclosporineTacrolimusBusulfanMesenchymal Stem Cell TransplantationFlow CytometryBlood CellsRetroviridaeSurvival RateWaiting ListsDonor SelectionTissue TransplantationLeukemia, Myeloid, AcuteFollow-Up StudiesUnrelated DonorsCell LineFetal BloodCorneal TransplantationHLA AntigensT-LymphocytesHematopoietic Cell Growth FactorsCell DivisionLeukemia, Myelogenous, Chronic, BCR-ABL PositiveChimerismCadaverGenetic VectorsAcute DiseaseAnemia, AplasticLiver DiseasesTransduction, GeneticLeukemia, MyeloidBrain Tissue TransplantationLiverMice, SCIDRemission InductionAntigens, CDStem CellsFacial TransplantationMycophenolic AcidAntilymphocyte SerumGranulocytesMyelodysplastic Syndromes
HSCTOutcomesTransplantBlood and Marrow TransplantationProgenitorDonorAutologous hematopoieticAlloHCTMultipotent hematopoietic stemEngraftmentChemotherapyIndicationsSurvivalTransplantsPatients with myelodysplastic syndromeMalignanciesGVHDMarrowHuman leukocyOutcomeReconstitutionUmbilicalClinicalImmuneDonorsHSCsSickleAplastic anemiaPeripheral blood stem cellsDestroyed tissue anGraftOrganConditioningPost-transplantationRelapsing-remitting multipleEfficacyCordCancer
HSCT24
Outcomes7
Transplant24
  • The Worldwide Network for Blood and Marrow Transplantation reported the millionth transplant to have been undertaken in December 2012. (wikipedia.org)
  • Hematopoietic cell transplant is currently the only known cure for myelodysplastic syndrome. (curetoday.com)
  • For an allogeneic stem cell transplant , after the bone marrow is destroyed, the patient receives blood-forming stem cells from another person - the donor," the American Cancer Society explained. (curetoday.com)
  • Stem cell transplant side effects can include low blood counts and graft-versus-host disease and can potentially be life-threatening, according to the American Cancer Society. (curetoday.com)
  • Novice nurses with limited pediatric clinical experience and no stem cell transplant experience. (aphon.org)
  • These nurses may know adult stem cell transplant, but have not cared for pediatric patients. (aphon.org)
  • Research and Development of new and improved transplant, cell therapy and immunosuppression procedures. (ebmt.org)
  • Data on 68 146 hematopoietic stem cell transplants (HSCTs) (53% autologous and 47% allogeneic) gathered by 1566 teams from 77 countries and reported through their regional transplant organizations were analyzed by main indication, donor type and stem cell source for the year 2012. (unisg.ch)
  • Total marrow and lymphoid irradiation may allow a greater dose of radiation to be delivered to the bone marrow as a preparative regimen before hematopoietic cell transplant while causing less side effects to normal organs than standard total body irradiation. (survivornet.com)
  • TRANSPLANT: Patients undergo hematopoietic cell transplantation on day 0. (survivornet.com)
  • This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT). (ucsd.edu)
  • The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab. (ucsd.edu)
  • Hematopoietic cell transplantation is, to date, the only curative therapy for SCD, but its application is limited by availability of a suitable HLA-matched donor and lack of awareness of the benefits of transplant. (duke.edu)
  • Included in this study are 1000 recipients of HLA-identical sibling transplants performed between 1986 and 2013 and reported to the European Society for Blood and Marrow Transplantation, Eurocord, and the Center for International Blood and Marrow Transplant Research. (duke.edu)
  • Blood and Marrow Transplant Research [CIBMTR] in 2004), the European Research Project on Cord Blood Transplantation (Eurocord) in 1993, and the Japanese Cord Blood Banking Network in 1996-expedited the clinical evaluation of the efficacy and safety of transplantation of cord blood from unrelated donors. (nationalacademies.org)
  • Up to 4.25 ILNA points may be applied to Basic Concepts for Transplantation OR Early Post-Transplant Management OR Pre-Transplant Care OR Types of Transplants and Sources of Stem Cells. (ons.org)
  • With the increase in organ transplantation and improved survival of transplant recipients, the incidence of disease will likely increase in the coming years. (cdc.gov)
  • Related transplant donors must be proven not to have Fanconi anemia in order for a transplantation to succeed. (medscape.com)
  • A bone marrow transplant is a procedure to replace damaged or diseased bone marrow with healthy bone marrow stem cells. (medlineplus.gov)
  • The stem cells are frozen and stored until they are needed for a transplant. (medlineplus.gov)
  • A stem cell transplant is usually done after chemotherapy and radiation is complete. (medlineplus.gov)
  • Haematopoietic stem cell transplants have been performed in more than 1 500 000 patients (both autologous and allogeneic) to date.1 Although haematological cancers remain the main indication, haematopoietic stem cell transplants are increasingly considered in the treatment of non-malignant disorders and genetic diseases such as haemoglobinopathies (sickle cell anaemia, thalassaemia) that can benefit greatly from this type of transplant. (who.int)
  • Under immunosuppression conditions, all infectious foci can be activated and, for this reason, all active infections in hematopoietic stem cell pre-transplant patients must be eradicated prior to transplant so as to prevent or reduce the risk of systemic complications in these patients. (bvsalud.org)
  • Aim: Present a case report of dental care provided to a non-Hodgkin lymphoma patient with an urgent need for hematopoietic stem cell transplant. (bvsalud.org)
Blood and Marrow Transplantation4
  • In 2006, 50,417 first HSCTs were recorded worldwide, according to a global survey of 1,327 centers in 71 countries conducted by the Worldwide Network for Blood and Marrow Transplantation. (wikipedia.org)
  • Worldwide, approximately 90,000 first HSCTs-53% autologous and 47% allogeneic-are performed every year, according to the World Wide Network of Blood and Marrow Transplantation. (medscape.com)
  • We tested this novel hypothesis in over 6,000 HCT from 8/8 HLA-matched UD reported to the European Group for Blood and Marrow Transplantation (EBMT), to demonstrate that HLA-DPB1 non-TPHE mismatches were associated with worse relapse-free survival and overall survival than TPHE mismatches, present in 21.7% of single HLA-DPB1 disparate pairs. (haematologica.org)
  • Title : Preventing opportunistic infections after hematopoietic stem cell transplantation : the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and Beyond Personal Author(s) : Sullivan, Keith M.;Dykewicz, Clare A.;Longworth, David L.;Boeckh, Michael;Baden, Lindsey R.;Rubin, Robert H.;Sepkowitz, Kent A. (cdc.gov)
Progenitor7
  • Although most clinicians would agree that hematopoietic progenitor cell transplantation after reinduction therapy is frontline therapy for these patients, there is no consensus as to what type of hematopoietic progenitor cell transplantation promises the best event-free and overall survival. (jnccn.org)
  • 1 - 3 However, those with relapsed and/or refractory (R/R) disease have had a historically dismal OS of ≤30% despite reinduction therapy and autologous hematopoietic progenitor cell transplantation (autoHCT) ( Figure 1 ). (jnccn.org)
  • B lood cell differentiation begins with multipotent hematopoietic progenitor cells (HPCs), which are located in the marrow spaces of the bone. (nationalacademies.org)
  • As the cells reproduce, they commit to a particular task or cell line and become known as committed progenitor cells . (nationalacademies.org)
  • These committed progenitor cells are difficult to discern from the original multipotent cells but can be cultured to form colonies of specific types of blood cells (Guyton and Hall, 2000). (nationalacademies.org)
  • Umbilical cord blood is a rich source of these committed progenitor cells and, presumably, multipotent HPCs (Knudtzon, 1974). (nationalacademies.org)
  • A review of the British Society for Histocompatibility and Immunogenetics (BSHI) "Guideline for selection and HLA matching of related, adult unrelated donors and umbilical cord units for haematopoietic progenitor cell transplantation" was undertaken by a BSHI appointed writing committee. (bvsalud.org)
Donor26
  • It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from an identical twin). (wikipedia.org)
  • In 2014, according to the World Marrow Donor Association, stem-cell products provided for unrelated transplantation worldwide had increased to 20,604 (4,149 bone-marrow donations, 12,506 peripheral blood stem-cell donations, and 3,949 cord-blood units). (wikipedia.org)
  • In contrast to the expected mixed chimerism that usually occurs in the absence of conditioning, we found in our patients 100% donor cell engraftment based on fluorescence in situ hybridization (FISH) and microsatellite techniques. (nih.gov)
  • Subset analysis of the engrafted cells using a multiparametric system enabling a combined analysis of morphology, immunophenotyping and FISH showed that both T and B lymphocytes and myeloid cells were of donor origin in two patients, while T lymphocytes and myeloid cells were of donor origin in the third. (nih.gov)
  • Alloreactive donor T cells are important mediators of both relapse control by graft- versus -leukemia (GvL) effects, and of GvHD. (haematologica.org)
  • 1 In unrelated donor (UD)-HCT, frequent human leukocyte antigen (HLA)-DPB1 disparity is the target of T-cell alloreactivity, contributing to both leukemia control and GvHD. (haematologica.org)
  • Alloreactive donor T cells recognizing patient-specific genetic polymorphisms, including mismatched HLA allotypes, play a major role in both beneficial GvL and severe GvHD after UD-HCT. (haematologica.org)
  • African Americans and Caucasians were matched for age, donor-recipient HLA match, graft type and transplantation year. (aamds.org)
  • Direct and indirect antigen presentation lead to deletion of donor-specific T cells after in utero hematopoietic cell transplantation in mice. (ca.gov)
  • In utero hematopoietic cell transplantation (IUHCTx) is a promising method to induce donor-specific tolerance but the mechanisms of antigen presentation that educate host T cells and the relative importance of deletion vs. regulation in this setting are unknown. (ca.gov)
  • We studied the roles of direct and indirect antigen presentation (mediated by donor- and host-derived antigen presenting cells (APCs), respectively) in a mouse model of IUHCTx. (ca.gov)
  • We found that IUHCTx leads to precocious maturation of neonatal host DCs and that there is early differentiation of donor-derived DCs, even after transplantation of a stem cell source without mature APCs. (ca.gov)
  • We next performed allogeneic IUHCTx into donor-specific T cell receptor transgenic mice and confirmed that both direct and indirect antigen presentation lead to clonal deletion of effector T cells in chimeras. (ca.gov)
  • In wild-type mice, there was a similar deletion of effector cells without expansion of donor-specific Tregs. (ca.gov)
  • We also analyse the engraftment of donor stem cells into non-conditioned and conditioned hosts, quantifying the impact of different treatment scenarios. (uzh.ch)
  • We predict the time taken for mutant clones to expand within a host, as well as chimerism levels that can be expected following transplantation therapy, and the probability that a preconditioned host is reconstituted by donor cells. (uzh.ch)
  • Eight patients received conditioning with fludarabine and low-dose total body irradiation followed by hematopoietic cell transplantation from an HLA-matched sibling donor. (aacrjournals.org)
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
  • Majority of patients (97%) were taking newer tri-azole prophylaxis (posaconazole) as per standard centre protocol.Results: Pre-IFD cases were similar to those without pre-IFD in gender, age, disease type, stem cell source, conditioning regimen and donor source whereas conditioning intensity, donor matching and HCTCI scores were significantly different. (kcl.ac.uk)
  • Introduction: In the United States, autologous hematopoietic cell transplantation (autoHCT) has fallen out of favor over chemotherapy consolidation for non-high-risk acute myeloid leukemia (AML) when allogeneic hematopoietic cell transplantation (alloHCT) is unfeasible, which is common in racial minorities because of donor registry under-representation and socioeconomic challenges. (elsevierpure.com)
  • Results: In a cohort consisting of 442 HLA-matched sibling patient and donor pairs where the transplants were non T cell depleted, a strong association existed between clinical risk score and both the incidence of acute GvHD II-IV and chronic GvHD. (ncl.ac.uk)
  • A study by MacMillan et al reported that alternative donor hematopoietic cell transplantation had a high success rate in patients with Fanconi anemia who did not have a history of opportunistic infections or transfusions and who underwent conditioning with single fraction total body irradiation 300 cGy, cyclophosphamide, fludarabine, and antithymocyte globulin. (medscape.com)
  • Stem cells are removed from another person, called a donor. (medlineplus.gov)
  • Leukapheresis -- First, the donor is given several days of shots to help stem cells move from the bone marrow into the blood. (medlineplus.gov)
  • The red blood cells are returned to the donor. (medlineplus.gov)
  • Here, we report transmission of dengue virus to a peripheral blood stem cell recipient by a donor who had recently traveled to an area to which the virus is endemic. (cdc.gov)
Autologous hematopoietic2
  • Background and ObjectivesUncontrolled evidence suggests that autologous hematopoietic stem cell transplantation (AHSCT) can be effective in people with active secondary progressive multiple sclerosis (SPMS). (mssm.edu)
  • 0.001).DiscussionThe use of AHSCT in people with active SPMS is associated with a slowing of disability progression and a higher likelihood of disability improvement compared with standard immunotherapy.Classification of EvidenceThis study provides Class III evidence that autologous hematopoietic stem cell transplants prolonged the time to CDP compared with other DMTs. (mssm.edu)
AlloHCT3
Multipotent hematopoietic stem1
Engraftment5
Chemotherapy10
  • In these cases, the recipient's immune system is usually destroyed with radiation or chemotherapy before the transplantation. (wikipedia.org)
  • The patient is then treated with high-dose chemotherapy with or without radiotherapy with the intention of eradicating the patient's malignant cell population at the cost of partial or complete bone marrow ablation (destruction of patient's bone marrow's ability to grow new blood cells). (wikipedia.org)
  • The purpose is to deliver chemotherapy, immunotherapy, and/or radiation to eliminate malignancy, prevent rejection of new stem cells, and create space for the new cells. (medscape.com)
  • HCT is a procedure where healthy blood-forming cells are administered to replace a patient's cells destroyed by chemotherapy or radiation treatments. (curetoday.com)
  • using cells from bone marrow, blood, or less often, umbilical cord blood cells are given after high- or moderate-dose chemotherapy and/or radiation therapy. (msdmanuals.com)
  • Autologous transplantation conferred relapse-free and overall survival benefit over chemotherapy consolidation alone, the current standard in the United States, and it might constitute a valuable option for ethnic/racial minorities. (elsevierpure.com)
  • Ablative (myeloablative) treatment -- High-dose chemotherapy, radiation, or both are given to kill any cancer cells. (medlineplus.gov)
  • Stem cells are removed from you before you receive high-dose chemotherapy or radiation treatment. (medlineplus.gov)
  • After high-dose chemotherapy or radiation treatments, your stems cells are put back in your body to make normal blood cells. (medlineplus.gov)
  • Because of the patient's risk status, the physicians intended to perform allogeneic stem cell transplantation after induction and consolidation chemotherapy, which was scheduled to end in January 2013, and a conditioning chemotherapy regimen, which was planned to be given in March. (cdc.gov)
Indications2
Survival12
  • An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. (nature.com)
  • Hematopoietic cell transplantation improved survival among high-risk genetic subgroups of patients with myelodysplastic syndrome, a recent study found. (curetoday.com)
  • Our work provides a synthesis of previous algorithms, mechanistically based on HLA-DPB1 immunopeptidome divergence 5 and expression by residual leukemia cells, 6 , 7 respectively, into a new and integrative model for intelligent mismatching in UD-HCT, to improve survival for future patients. (haematologica.org)
  • In conclusion, reduced intensity transplantation showed excellent survival but higher relapse for AP myelofibrosis. (physiciansweekly.com)
  • The 5-year probabilities of overall survival adjusted for interval from diagnosis to transplantation, and performance score was 58% for African Americans and 73% for Caucasians. (aamds.org)
  • Although children, adolescents, and young adults with newly diagnosed B-cell non-Hodgkin's lymphoma enjoy excellent overall survival with current chemoimmunotherapy, those with relapsed and/or refractory disease have a dismal prognosis. (jnccn.org)
  • Children, adolescents, and young adults (CAYAs) with newly diagnosed B-cell non-Hodgkin's lymphoma (B-NHL) enjoy excellent overall survival (OS) with current frontline chemoimmunotherapy. (jnccn.org)
  • Kaplan-Meier curve showing probability of overall survival in children and adolescents with mature B-cell non‐Hodgkin's lymphoma with refractory or relapsed disease during or after therapy in the FAB/LMB96 international study. (jnccn.org)
  • Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. (jnccn.org)
  • The survival rate after transplantation from alternative donors is improving, depending on the completeness of the HLA-matching. (medscape.com)
  • The benefits of human tissue transplantation can be seen in both children and adults, including in survival rates following severe burn trauma, recovery of movement, closure of chronic wounds, rehabilitation of heart function and restoration of sight. (who.int)
  • Kidney transplantation is a far more favourable treatment modality versus dialysis in terms of survival, quality of life and cost-effectiveness. (who.int)
Transplants4
  • Other conditions treated with stem cell transplants include sickle cell disease, myelodysplastic syndrome, neuroblastoma, lymphoma, Ewing's sarcoma, desmoplastic small round cell tumor, chronic granulomatous disease, Hodgkin's disease and Wiskott-Aldrich syndrome. (wikipedia.org)
  • [ 1 ] More than half of autologous transplantations are performed for multiple myeloma and non-Hodgkin lymphoma , and the vast majority of allogeneic transplants are performed for hematologic and lymphoid cancers. (medscape.com)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • One of the best examples of these two contrasting aspects of T-cell alloreactivity is donorrecipient HLA-DPB1 disparity, present in over 80% of transplants from UD. (haematologica.org)
Patients with myelodysplastic syndrome3
Malignancies3
  • Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study. (ctsicn.org)
  • High-dose therapy with allogeneic hematopoietic cell transplantation (HCT) offers effective control and potential cure of hematopoietic malignancies, but with the cost of associated morbidity that includes adverse effects on quality of life (QOL). (usf.edu)
  • Hematopoietic stem cell transplantation has become a major treatment option for patients with hematopoietic malignancies and immune deficiencies. (cdc.gov)
GVHD3
  • Among 1462 patients who had allogeneic hematopoietic cell transplantation (HCT) between January 2000 and December 2005, 116 (7.9%) developed stage 3-4 gut GVHD. (nature.com)
  • Relapse and graft- versus -host disease (GvHD) are the main impediments to the clinical success of allogeneic hematopoietic cell transplantation (HCT) in curing malignant blood disorders. (haematologica.org)
  • 2 We have previously shown that two biological models of HLA-DPB1 mismatching, namely permissiveness according to T-cell epitope (TCE) groups and genetically determined high-expression levels, are individually associated with the risks of non-relapse mortality and GvHD/relapse, respectively. (haematologica.org)
Marrow16
Human leukocy1
Outcome6
Reconstitution4
  • CMV epitope selection and its use in T cell reconstitution in patients undergoing haematopoietic stem cell transplantation. (ucl.ac.uk)
  • Delayed and incomplete reconstitution of the ADAPTIVE IMMUNE system in particular involving T-CELLS is associated with increase or relapse of infection. (bvsalud.org)
  • Here, we assessed the expression of macrophage-1 antigen (MAC-1) on HSCs during regeneration following transplantation and observed a transient increase in MAC-1 expression during the early reconstitution phase. (lu.se)
  • Serial transplantation experiments demonstrated that reconstitution potential was highly enriched in the MAC-1 + portion of the HSC pool. (lu.se)
Umbilical2
  • Stem cells are removed from a newborn baby's umbilical cord right after birth. (medlineplus.gov)
  • Umbilical cord blood cells are very immature so there is less of a need for perfect matching. (medlineplus.gov)
Clinical2
Immune4
  • Total body irradiation can lower the relapse rate but has some fatal side effects such as irreversible damage to normal internal organs and graft-versus-host disease (a complication after transplantation in which donor's immune cells recognize the host as foreign and attack the recipient's tissues). (survivornet.com)
  • Describe the kinetics of immune cell recovery. (survivornet.com)
  • The cell mediated immune response notably that mediated through cytotoxic T lymphocytes (CTL) is essential in the maintenance of viral latency and the resolution of primary infections. (ucl.ac.uk)
  • Simpson RJ, Bigley AB, Agha N, Hanley PJ, Bollard CM. Mobilizing Immune Cells With Exercise for Cancer Immunotherapy. (ctsicn.org)
Donors3
  • The International Histocompatibility Working Group (IHWG) is a collaborative international effort to increase the availability and efficacy of hematopoietic cell transplantation (HCT) from alternative donors through an improved understanding of the genetic barrier. (ihiw18.org)
  • Patients received 14 g/m(2)/day treosulfan i.v. on days -6 to -4, 30 mg/m(2)/day fludarabine i.v. on days -6 to -2, and 2 Gy TBI on day 0, followed by infusion of hematopoietic cells from related (n = 27) or unrelated (n = 69) donors . (bvsalud.org)
  • In May 2010, the Sixty-third World Health Assembly adopted resolution WHA63.22,1 in which it endorsed the updated WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation and provided strategic directions to support progress in human organ, tissue and cell donation with the aim of maximizing the benefits of transplantation, meeting the needs of recipients, protecting donors and ensuring the dignity of all involved. (who.int)
HSCs3
  • Mouse hematopoietic stem cells (HSCs) have been extensively defined both molecularly and functionally at steady state, while regenerative stress induces immunophenotypical changes that limit high purity isolation and analysis. (lu.se)
  • Moreover, in contrast to previous reports, we found that MAC-1 expression inversely correlates with cell cycling, and global transcriptome analysis showed that regenerating MAC-1 + HSCs share molecular features with stem cells with low mitotic history. (lu.se)
  • HSCs share molecular features with stem cells with low mitotic history. (lu.se)
Sickle2
  • Scholars@Duke publication: Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. (duke.edu)
  • Despite advances in supportive therapy to prevent complications of sickle cell disease (SCD), access to care is not universal. (duke.edu)
Aplastic anemia1
Peripheral blood stem cells1
Destroyed tissue an1
  • The patient's own stored stem cells are then transfused into his/her bloodstream, where they replace destroyed tissue and resume the patient's normal blood-cell production. (wikipedia.org)
Graft3
Organ1
  • Organ transplantation is often the best, if not the only, treatment for acute and chronic organ failure. (who.int)
Conditioning1
  • Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
Post-transplantation1
  • At post transplantation day plus 3, antibiotic drug therapy was switched from piperacillin/tazobactam to meropenem. (cdc.gov)
Relapsing-remitting multiple1
Efficacy1
Cord1
  • In the last decade, the number of transplantations of HPCs derived from cord blood has increased, particularly for children. (nationalacademies.org)
Cancer5